⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28113085 | 0.67 | — | — | |
| Water SCHEMBL27883112 | 0.59 | — | — | |
| SCHEMBL1078946 | 0.59 | ALDH1A1 (0.46) | — | |
| SCHEMBL60898 | 0.59 | — | — | |
| SCHEMBL16037462 | 0.59 | ALDH1A1 (1.00) | — | |
| SCHEMBL56391 | 0.59 | — | — | |
| SCHEMBL7016041 | 0.56 | — | — | |
| Lithium SCHEMBL10525716 | 0.56 | — | — | |
| SCHEMBL2683512 | 0.56 | — | — | |
| SCHEMBL16585787 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006523699-A | — | — | 2006-10-19 | — | — | JP | claimed |
| US-20060194838-A1 | Polymorphic form of montelukast sodium | MERCK SHARP & DOHME CORP. | 2006-08-31 | — | — | US | claimed |
| EP-1633357-A1 | POLYMORPHIC FORM OF MONTELUKAST SODIUM | Merck & Co., Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2004091618-A1 | POLYMORPHIC FORM OF MONTELUKAST SODIUM | MERCK FROSST CANADA LTD. (CA) | 2004-10-28 | — | — | WO | claimed |
| EP-4743462-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2026-05-20 | — | — | EP | disclosed |
| US-20250101034-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2025012643-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2025-01-16 | — | — | WO | disclosed |
| EP-4426704-A1 | CONDENSED PYRIDAZINE AMINE DERIVATIVES TREATING SCA3 | Skyhawk Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023081857-A1 | CONDENSED PYRIDAZINE AMINE DERIVATIVES TREATING SCA3 | SKYHAWK THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-1697344-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2266971-A2 | Hiv protease inhibiting compounds | Abbott Laboratories (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7834043-B2 | Prevent reproduct of aids virus | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100249181-A1 | HIV Protease Inhibiting Compounds | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1697344-A2 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050148623-A1 | Prevent reproduct of aids virus | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005058841-A2 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131017-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |